This has been strongly supported by a recent study [56] showing that expression of erbB3 is associated with worse survival in a variety of human cancers of breast, colorectal, gastric, melanoma, ovarian, head and neck, pancreatic, and cervical; and the influence of erbB3 may be greater in the tumors with erbB2 overexpression. This evidence concerns the gene ERBB3 and melanoma.